EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Ping-Feng Wu iD, Hsi-Hsun Lin, Hsin-Pai Chen, Po-Chieh Huang, Meng-Yu Ke

Health Science Reports · 2024-12 · 7 (12)

DOI: 10.1002/hsr2.70275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 18.12.2024. Verfasst von Ping-Feng Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine Taipei Veterans General Hospital Taipei Taiwan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences. We aimed to investigate the metabolic outcomes of PLWH by replacing rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) with RPV/tenofovir alafenamide (TAF)/FTC.

Methods

This retrospective study enrolled PLWH who changed from RPV/TDF/FTC to RPV/TAF/FTC between January 2019 and September 2023. Metabolic profiles were compared 1 year before and 3 years after changing cART using Cochran's Q and one‐way ANOVA. The independent risk factors for metabolic syndrome were analyzed using logistic regression.

Results

A total of 182 patients were enrolled. The prevalence of metabolic syndrome has increased from 28% to 40.7%. The prevalence of hypertension and abnormal lipid levels significantly increased in the first year after changing cART, but the prescription of medicine for dyslipidemia increased in the second year ( p = 0.025) and that for hypertension increased in the third year ( p < 0.001). In addition to the criteria, body mass index (BMI) before changing cART was the only predictor of metabolic syndrome in the third year (OR 1.36; 95% CI 1.19–1.55; p < 0.001). The prevalence of metabolic syndrome and BMI did not increase significantly during the second and third years.

Conclusions

A gradually higher prevalence of metabolic syndrome among PLWH occurred with changes from RPV/TDF/FTC to RPV/TAF/FTC but plateaued beyond 2 years. However, fewer drugs for dyslipidemia, diabetes, and hypertension were prescribed within the first year after changing cART.

Schlagwörter

Stichwörter der Autor:innen

HIVlipidsmetabolic syndrometenofovir alafenamidetenofovir disoproxil fumarate

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine Taipei Veterans General Hospital Taipei Taiwan.
  • School of Medicine National Yang-Ming Chiao Tung University Taipei Taiwan.
  • Institute of Clinical Medicine National Yang-Ming Chiao Tung University Taipei Taiwan.
  • Division of Infectious Diseases E-Da Dachang Hospital, I-Shou University Kaohsiung Taiwan.

ORCID-Profile: Ping-Feng Wu

Zitieren

APA

Wu, P. F., Lin, H. H., Chen, H. P., Huang, P. C., & Ke, M. Y. (2024). Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study. Health Science Reports, 7(12). https://doi.org/10.1002/hsr2.70275

Vancouver

Wu PF, Lin HH, Chen HP, Huang PC, Ke MY. Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study. Health Science Reports. 2024;7(12). doi:10.1002/hsr2.70275

BibTeX
@article{Wu2024,
  author = {Wu, Ping-Feng and Lin, Hsi-Hsun and Chen, Hsin-Pai and Huang, Po-Chieh and Ke, Meng-Yu},
  title = {Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study},
  journal = {Health Science Reports},
  year = {2024},
  volume = {7},
  number = {12},
  doi = {10.1002/hsr2.70275}
}
Kostenlos starten →